Negative results were seen with trials using metformin and aromatase inhibitors in hormone receptor (HR)-positive breast cancer [11], metformin/doxorubicin/cyclophosphamide in human epidermal growth factor receptor 2 (HER2)-negative breast cancer [12], and metformin and erlotinib in patients with metastatic triple negative breast cancer [13]. This evidence concerns the gene ERBB2 and breast carcinoma.